JP7508441B2 - 五環式化合物の塩およびそれらの結晶 - Google Patents

五環式化合物の塩およびそれらの結晶 Download PDF

Info

Publication number
JP7508441B2
JP7508441B2 JP2021504108A JP2021504108A JP7508441B2 JP 7508441 B2 JP7508441 B2 JP 7508441B2 JP 2021504108 A JP2021504108 A JP 2021504108A JP 2021504108 A JP2021504108 A JP 2021504108A JP 7508441 B2 JP7508441 B2 JP 7508441B2
Authority
JP
Japan
Prior art keywords
thieno
compound
crystal
diffraction
monohydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504108A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020179781A5 (https=
JPWO2020179781A1 (https=
Inventor
賢史 吉田
芳章 大橋
環 星川
信明 佐藤
郁雄 櫛田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JPWO2020179781A1 publication Critical patent/JPWO2020179781A1/ja
Publication of JPWO2020179781A5 publication Critical patent/JPWO2020179781A5/ja
Application granted granted Critical
Publication of JP7508441B2 publication Critical patent/JP7508441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021504108A 2019-03-05 2020-03-03 五環式化合物の塩およびそれらの結晶 Active JP7508441B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019039349 2019-03-05
JP2019039349 2019-03-05
PCT/JP2020/008889 WO2020179781A1 (ja) 2019-03-05 2020-03-03 五環式化合物の塩およびそれらの結晶

Publications (3)

Publication Number Publication Date
JPWO2020179781A1 JPWO2020179781A1 (https=) 2020-09-10
JPWO2020179781A5 JPWO2020179781A5 (https=) 2023-02-28
JP7508441B2 true JP7508441B2 (ja) 2024-07-01

Family

ID=72337486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504108A Active JP7508441B2 (ja) 2019-03-05 2020-03-03 五環式化合物の塩およびそれらの結晶

Country Status (11)

Country Link
US (1) US11420980B2 (https=)
EP (1) EP3936189A4 (https=)
JP (1) JP7508441B2 (https=)
KR (1) KR102921161B1 (https=)
CN (1) CN113646046B (https=)
AU (1) AU2020233452B2 (https=)
BR (1) BR112021015979A2 (https=)
CA (1) CA3129764A1 (https=)
MX (1) MX2021009774A (https=)
TW (2) TWI870286B (https=)
WO (1) WO2020179781A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020179780A1 (ja) 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物
PT119624A (pt) * 2024-07-29 2026-01-29 Silva Escada Guilherme Máquina modular para a dobragem de tubos de pvc

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033666A2 (en) 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
DD258234A1 (de) 1987-03-05 1988-07-13 Univ Leipzig Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (https=) * 1990-02-08 1993-01-01 Pfizer
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
KR100203456B1 (ko) * 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
AU2005299031B2 (en) 2004-10-20 2011-11-10 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
US9314318B2 (en) * 2008-08-26 2016-04-19 Zest Ip Holdings, Llc Dental anchor apparatus and method
JP6557441B1 (ja) * 2017-09-07 2019-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式化合物
WO2020179780A1 (ja) 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033666A2 (en) 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEMDAN, M. M. et al.，Chemical and Pharmaceutical Bulletin，2015年，Vol. 63，pp. 450-456

Also Published As

Publication number Publication date
EP3936189A1 (en) 2022-01-12
BR112021015979A2 (pt) 2021-10-05
KR20210135223A (ko) 2021-11-12
US11420980B2 (en) 2022-08-23
CN113646046A (zh) 2021-11-12
KR102921161B1 (ko) 2026-02-02
TWI849070B (zh) 2024-07-21
MX2021009774A (es) 2021-09-08
JPWO2020179781A1 (https=) 2020-09-10
CN113646046B (zh) 2024-05-17
AU2020233452A1 (en) 2021-09-02
EP3936189A4 (en) 2022-12-14
TW202430531A (zh) 2024-08-01
WO2020179781A1 (ja) 2020-09-10
AU2020233452B2 (en) 2025-04-10
TW202100531A (zh) 2021-01-01
US20210024541A1 (en) 2021-01-28
TWI870286B (zh) 2025-01-11
CA3129764A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
JP5599610B2 (ja) Ｈｓｐ９０の阻害による神経変性疾患の処置
US10022357B2 (en) Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
JP6557441B1 (ja) 五環式化合物
JP2021528488A (ja) Ｓａｒｍ１阻害剤
EP2388000A2 (en) Neuroprotectant containing heterocyclic compound having specific structure
JP7508441B2 (ja) 五環式化合物の塩およびそれらの結晶
RU2820938C2 (ru) Соль пентациклического соединения и его кристалл
JP2001002572A (ja) ニューロトロフィン作用増強剤
WO2026035920A1 (en) (2-oxo-2h-chromen-3-yl) scaffold based carboxamide analogs as potent inhibitors of tau protein fibrils
BR112020003197B1 (pt) Composto pentacíclico
WO2019046534A1 (en) INDOLOQUINOLINE COMPOUNDS DEUTTERED
HK1164129A (en) Neuroprotectant containing heterocyclic compound having specific structure
HK1164114B (en) Antidepressant containing heterocyclic compound having specific structure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240619

R150 Certificate of patent or registration of utility model

Ref document number: 7508441

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150